Receptor-subtype binding affinity
Biochemical assay · Membranes from S115 cells expressing individual human α2A, α2B or α2C receptors; mouse α2D-expressing CHO membranes. [1]
JP-1302 had higher affinity for human α2C than for the other tested α2 subtypes. Values are Ki, not treatment concentrations.
| Endpoint | Reported result | Reference |
|---|---|---|
| Receptor binding affinity | Ki Human α2A: 3150±50 nM; human α2B: 1470±130 nM; human α2C: 28±2 nM; mouse α2D: 1700±200 nM. Mean±s.e.m.; minimum three repeat experiments. | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- At least six test-compound concentrations; exact range not specified in the read method.
- Exposure duration
- 30 min at room temperature
- Method
- Radioligand competition binding; nonspecific binding defined with 100 µM oxymetazoline.
- Vehicle
- DMSO
- Reported limits
- In-vitro salt form and final DMSO percentage not specified in the read methods.
Methods and source locations
Compound reported in the paper: JP-1302; Compound label in the paper: JP-1302; in-vitro salt form not specified
Active-moiety pharmacology of JP-1302; these data do not establish dihydrochloride-specific potency or validate an Adooq lot.
Table 1 (tbl1), binding-affinity column and footnote; Methods radioligand-binding assays; Drugs; Figure 1
Receptor binding affinity: [3H]-rauwolscine for human subtypes; [3H]-RX821002 for mouse α2D; Cheng–Prusoff conversion of competition IC50. — Table 1 (tbl1), binding-affinity column and footnote; Methods radioligand-binding assays; Drugs; Figure 1